Day: August 12, 2025

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis (“EoE”)Additional data from cohorts 5–8 from Phase 1b/2a available in October 2025VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar...

LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Second Quarter Financial HighlightsOn August 12, 2025, the Board of Navigator Holdings Ltd., (NYSE: NVGS) (“Navigator Holdings”, “Navigator Gas”, “our”, “we”, “us” or the “Company”) declared a cash dividend of $0.05 per share of the Company’s common stock for the quarter ended June 30, 2025, under the Company’s Return of Capital policy, payable on September 17, 2025, to all shareholders of record as of the close of business U.S. Eastern Time on August 28, 2025 (the “Dividend”).Also as part of the Company’s Return of Capital policy for the quarter ended June 30, 2025, the Company expects to repurchase approximately $2.1 million of its common stock between August 14, 2025, and September 30, 2025, subject to operating needs, market conditions, legal requirements, stock...

SEOUL, South Korea, Aug. 12, 2025 (GLOBE NEWSWIRE) — DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, today announced unaudited financial results for the second quarter ended June 30, 2025. Beginning with the fourth quarter of 2024, the Company is reporting its financial results in accordance with International Financial Reporting Standards (“IFRS”). As such, the financial results for the second quarter of 2025, as well as the comparable period for 2024, reflect IFRS. The Company previously reported its financial results in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Second Quarter 2025 vs. Second Quarter 2024 Summary:Revenue was $84.8 million in the second...

SUGAR LAND, Texas, Aug. 12, 2025 (GLOBE NEWSWIRE) — Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights:Generated revenue of $248.0 million, up $19.4 million, or 8.5% over the second quarter of 2024. Grew gross margin to $68.1 million, a $4.5 million, or 7.1% increase over the second quarter of 2024. Reported net loss of $4.3 million. Increased consolidated Adjusted EBITDA1 by 12.4% to $24.5 million (9.9% of consolidated revenue) from $21.8 million (9.5% of consolidated revenue) for the second quarter of 2024. Lowered Adjusted...

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments. “The randomization of the first participant in our CATT1 Phase 3 trial earlier this month reflects our continued momentum in advancing cadisegliatin,”...

MARKHAM, Ontario, Aug. 12, 2025 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2025. HighlightsAverage Same Property Occupancy in retirement segment up 150 basis points (“bps”) year-over-year to 92.1% in Q2 2025 and further increased to 93.1% in July 2025 Revenue, Proportionate Basis, excluding One-Time Items, increased by 17.4% to $253.6 million in Q2 2025 Same Property Net Operating Income (“NOI”), excluding One-Time Items, up 8.2% to $45.1 million in Q2 2025Retirement Segment up 12.3% year-over-year in Q2 2025 Long-Term Care (“LTC”) Segment up 4.8% year-over year in Q2 2025Adjusted Funds from Operations (“AFFO”), excluding One-Time Items, increased by 21.0%, and on a per share decreased 4.0% in Q2 2025 Completed...

ATHENS, Greece, Aug. 12, 2025 (GLOBE NEWSWIRE) — Okeanis Eco Tankers Corp. (together with its subsidiaries, unless context otherwise dictates, “OET” or the “Company”) (NYSE: ECO, OSE: OET) today reported its unaudited condensed financial results for the second quarter and six-month period of 2025, which are attached to this press release. Financial performance of the Second Quarter Ended June 30, 2025Revenues of $93.9 million in Q2 2025, compared to $112.0 million in Q2 2024. Profit of $26.9 million in Q2 2025, compared to $39.6 million in Q2 2024. Vessel operating expenses of $11.5 million in Q2 2025, compared to $10.8 million in Q2 2024. Earnings per share of $0.84 in Q2 2025, compared to $1.23 in Q2 2024. Cash (including restricted cash) of $65.3 million as of June 30, 2025, compared to $98.1 million as of June 30, 2024.Financial...

– Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 – – FA (SGT-212): Phase 1b trial initiation expected in Q4 2025 – – CPVT (SGT-501): Phase 1b trial initiation expected in Q4 2025 – – Capsids (AAV-SLB101): Over 25 agreements or licenses with academic labs, institutions and corporations for the use of AAV-SLB101 have been executed – – Cash: Company ended Q2 2025 with $268.1 million in cash, cash equivalents and available-for-sale securities; Solid has anticipated cash runway into H1 2027 – CHARLESTOWN, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision,...